Gapping up
In reaction to strong earnings/guidance: XENE +5.5%, HON +0.6%
M&A news: RBC +9.7% (merson has agreed to sell its Power Transmission Solutions business unit to Regal Beloit Corporation (RBC) for $1.44 bln), TLM +5.1% (cont M&A spec), PETM +4.7% (still checking), IRM +4.3% (confirms proposal to acquire Recall Holdings for A$7.00 per share by scheme of arrangement), AA +2% (to acquire TITAL to expand global growth platform for titanium aerospace components
Select oil/gas related names showing strength: OAS +5.8%, PTR +3.5%, STO +2%, RIG +1.9%, BAS +1.7%, OXY +1.1%, RDS.A +0.7%
Other news: FRO +13.3% (cont strength), CANF +7.4% (Second part of the Glaucoma Phase II study has been approved in a European country), KGJI +6.9% (announces termination of at market issuance sales agreement), RLYP +4.8% (announces FDA acceptance of New Drug Application for Patiromer for Oral Suspension to treat hyperkalemia), ABGB +4.4% (Signs power purchase agreement and secures financing of Xina Solar One), BEBE +3.8% (Jim Wiggett has been named CEO), RMTI +2.4% (favorable commentary on Friday's Mad Money), AHC +2% (closed on the sale of its former South Plant facility), RCL +1.6% (refinanced the Brilliance of the Seas by terminating the leasing of the ship under the 25-year operating lease originally entered into in July 2002 and acquiring the ship for a purchase price of ~$275 mln), AAL +1.6% (to be added to Nas 100), JRJC +1.6%, SUNE +1.6% (announced that the National Energy Commission in Chile has awarded SunEdison a contract to supply 570 gigawatt hours of clean energy a year), NOA +1.3% (announces ~1.77 mln share purchase program in the US ), CRAY +1.3% (awarded $30 mln contract from the Department of Defense High Performance Computing Modernization Program), BCRX +1.3% (initiation of a phase 1 clinical trial of BCX4430), ALXN +1.2% (announced that its Board has authorized a new share repurchase program of up to $500 mln)
Analyst comments: CRUS +6.2% (upgraded to Overweight from Underweight at Barclays), CY +3.4% (upgraded to Outperform from Neutral at Wedbush), NOW +2.8% (upgraded to Top Pick at RBC Capital Mkts), TWTR +2.6% (initiated with a Mkt Outperform at JMP Securities), FCAU +2.5% (upgraded to Neutral from Underperform at Exane BNP Paribas), ORCL +2.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), ECPG +2% (upgraded to Overweight from Neutral at Piper Jaffray), XOM +1.1% (upgraded to Market Perform from Underperform at BMO Capital Markets)
In reaction to strong earnings/guidance: XENE +5.5%, HON +0.6%
M&A news: RBC +9.7% (merson has agreed to sell its Power Transmission Solutions business unit to Regal Beloit Corporation (RBC) for $1.44 bln), TLM +5.1% (cont M&A spec), PETM +4.7% (still checking), IRM +4.3% (confirms proposal to acquire Recall Holdings for A$7.00 per share by scheme of arrangement), AA +2% (to acquire TITAL to expand global growth platform for titanium aerospace components
Select oil/gas related names showing strength: OAS +5.8%, PTR +3.5%, STO +2%, RIG +1.9%, BAS +1.7%, OXY +1.1%, RDS.A +0.7%
Other news: FRO +13.3% (cont strength), CANF +7.4% (Second part of the Glaucoma Phase II study has been approved in a European country), KGJI +6.9% (announces termination of at market issuance sales agreement), RLYP +4.8% (announces FDA acceptance of New Drug Application for Patiromer for Oral Suspension to treat hyperkalemia), ABGB +4.4% (Signs power purchase agreement and secures financing of Xina Solar One), BEBE +3.8% (Jim Wiggett has been named CEO), RMTI +2.4% (favorable commentary on Friday's Mad Money), AHC +2% (closed on the sale of its former South Plant facility), RCL +1.6% (refinanced the Brilliance of the Seas by terminating the leasing of the ship under the 25-year operating lease originally entered into in July 2002 and acquiring the ship for a purchase price of ~$275 mln), AAL +1.6% (to be added to Nas 100), JRJC +1.6%, SUNE +1.6% (announced that the National Energy Commission in Chile has awarded SunEdison a contract to supply 570 gigawatt hours of clean energy a year), NOA +1.3% (announces ~1.77 mln share purchase program in the US ), CRAY +1.3% (awarded $30 mln contract from the Department of Defense High Performance Computing Modernization Program), BCRX +1.3% (initiation of a phase 1 clinical trial of BCX4430), ALXN +1.2% (announced that its Board has authorized a new share repurchase program of up to $500 mln)
Analyst comments: CRUS +6.2% (upgraded to Overweight from Underweight at Barclays), CY +3.4% (upgraded to Outperform from Neutral at Wedbush), NOW +2.8% (upgraded to Top Pick at RBC Capital Mkts), TWTR +2.6% (initiated with a Mkt Outperform at JMP Securities), FCAU +2.5% (upgraded to Neutral from Underperform at Exane BNP Paribas), ORCL +2.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), ECPG +2% (upgraded to Overweight from Neutral at Piper Jaffray), XOM +1.1% (upgraded to Market Perform from Underperform at BMO Capital Markets)